Comparison of therapeutic effect of low-dose low-molecular-weight heparin (enoxaparin) vs. oral prednisone in treatment of patients with lichen planus; A clinical trial

Authors
Fariba Iraji 1
Ali Asilian 1
Ahmad Saeidi 1
Amir Hossein Siadat 1
Ali Reza Saeidi 2
Akbar Hassanzadeh 3
1 Department of Dermatology, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Science, Isfahan, Iran
2 Dental Student's Research Center, School of Dentistry, Isfahan University of Medical Science, Isfahan, Iran
3 Department of Epidemiology and Biostatic, School of Health, Isfahan University of Medical Science, Isfahan, Iran
Abstract
Background: The aim of this study was to evaluate and compare the therapeutic efficacy of subcutaneous enoxaparin versus oral prednisone (as a standard treatment) in patients with disseminated lichen planus.
Materials and Methods: In this parallel randomized clinical trial study, overall 48 patients completed the study. 25 patients were treated with subcutaneous enoxaparin 5 mg weekly and 23 patients with 0.5 mg/kg prednisone orally daily until complete remission or a maximum of 8 weeks. The results of itching severity, extent of active lesions and drug side effects were compared. In remission, patients were followed for 6 months for recurrent lesions.
Results: In enoxaparin group, 8 patients (32%) had complete remission and 10 patients (40%) had partial improvement. In the oral prednisone group, 16 patients (69.6%) had complete remission and 6 patients (26.1%) had partial improvement (P = 0.005). Average size of active lesions in both groups decreased significantly after treatment, but analysis of covariance showed that the mean lesion size after treatment in the oral prednisone group was significantly lower than the enoxaparin group (P = 0.005). The relapse rate from improved patients in the enoxaparin group was 6 (33%) and in oral prednisone group was 9 (40.9%, P = 0.083). In the enoxaparin group no serious complications was seen. But 22% in the oral prednisone group show side effect, the most common complications were dyspepsia.
Conclusion: Low dose enoxaparin on lichen Planus have therapeutic effect and is important for the least side effects but not as much as oral prednisone. But it could be accepted as an alternative treatment.

Keywords

1. James WD, Berger TG, Elston DM. Lichen planus and related conditions. In: James WD, Berger TG, Elston DM, editors. Andrews disease of the skin clinical dermatology. 10 th ed. New York: Elsevier; 2006. p. 217-30.  Back to cited text no. 1
    
2. Akdeniz S, Harman M, Atmaca S, Yaldiz M. The management of lichen planus with low-molecular-weight heparin (enoxaparin). Int J Clin pract 2005;59:1268-71.  Back to cited text no. 2
[PUBMED]    
3. Tetsuo S, Yoko K. Lichen planus and lichenoid dermatosis. In: Bolognia JL, Jorizzo JL, Rapini RP, editors. Dermatology. 2 nd ed. New York: Mosby; 2008. p. 159.  Back to cited text no. 3
    
4. Al-hashimi I, Schifter M, Lockhart PB, Wary D, Brennan M, Migliorati CA, et al. Oral lichen planus and oral lichenoid lesions: Diagnostic and therapeutic considerations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;25:1-12.  Back to cited text no. 4
    
5. Setterfield JF, Blach MM, Challacombe SJ. The management of oral lichen planus. Clin Exp Dermatol 2000;25:176-82.  Back to cited text no. 5
    
6. Mark RP, Mazen SD. Lichen planus. In: Wolff K, Goldsmith LA, Katz SI, editors. Fitzpatricks dermatology in general medicine, 7 th ed. New York: McGraw Hill; 2008. p. 244-54.  Back to cited text no. 6
    
7. Stefanidou MP, Ioannidou DJ, Panayiotides JG, Tosca AD. low molecular weight heparin; a novel alternative therapeutic approach for lichen planus. Br J Dermatol 1999;141:1040-45.  Back to cited text no. 7
[PUBMED]    
8. Kobkan T, Kittipong D. Steroids in the treatment of lichen planus: A review. J Oral Sci 2008;50:377-85.  Back to cited text no. 8
    
9. Thongprason K, Dhanuthai K, Sarideechaigul W, Chaiyarit P, Chaimusig M. Expression of TNFa in oral lichen planus treated with fluocinolone acetonide 0.1%. J Oral Pathol Med 2006;35:161-6.  Back to cited text no. 9
    
10. Ferahbas A, Uksal U, Kutlugun C, Contas O. Low-molecular-weight heparin (enoxaparin) in the treatment of lichen planus. J Eur Acad Dermatol Venereol 2003;17:601-19.  Back to cited text no. 10
    
11. Hodak E, Yosipovitch G, David M, Ingber A, Chorev L, Lider O, et al. Low-dose Low-molecular-weight heparin (enoxaparin) is beneficial in lichen planus. J Am Acad Dermatology 1998;38:564-8.  Back to cited text no. 11
    
12. Pacheco H, Kerdel F. Successful treatment of lichen planus with low- molecular-weight heparin: A case series of seven pationts. J Dermatol Treat 2001;12:123-6.  Back to cited text no. 12
    
13. Ria R, Kaur I, Kumar B. Low-dose low-molecular-weight heparin in lichen planus. J Am Acad Dermatol 2002;46:141-3.  Back to cited text no. 13
    
14. Yasar S, Serdar ZA, Goktay F, Doner N, Tanzer C, Akkaya D, et al. The successful treatment of palmoplantar hyperkeratotic lichen planus with enoxaparin. Indian J Dermatol Venereol Leprol 2011;77:64-6.  Back to cited text no. 14
[PUBMED]  Medknow Journal  
15. Femiano F, Scully C. Oral lichen planus: Clinical and histological evaluation in an open trial using a low molecular weight heparinoid (sulodexide). Int J Dermatol 2006;45:986-9.  Back to cited text no. 15
[PUBMED]    
16. Neville JA, Hancox JG, Williford PM, Yosipovich G. Treatment of severe cutaneous ulcerative lichen planus with low molwcular weight heparin in a patient with hepatitis C. Cutis 2007;76:37-40.  Back to cited text no. 16
    
 
Advanced Biomedical Research
Volume 2013, July
July 2013
Pages 1-5